亚洲地区代谢相关脂肪性肝病流行情况

黄炜燊

doi:10.12449/JCH250901

亚洲地区代谢相关脂肪性肝病流行情况

DOI: 10.12449/JCH250901

黄炜燊^{1, 2, , ,}

1.
香港中文大学医学院内科及药物治疗学系医学数据分析中心，香港 999077
2.
香港中文大学消化疾病研究所消化疾病国家重点实验室，香港 999077

基金项目:

中国香港研究资助委员会一般研究基金 (14106923);

香港中文大学直接研究基金 (2024.065);

国家重点研发计划 (2023ZD0508700)

利益冲突声明：黄炜燊曾担任艾伯维、阿斯利康、勃林格殷格翰、Echosens、礼来、吉利德、Intercept、Inventiva、默克、诺和诺德、辉瑞、Sagimet Biosciences、TARGET PharmaSolutions、Visirna等公司的顾问或咨询委员会成员，并为雅培、艾伯维、Echosens、吉利德、诺和诺德及Unilab担任演讲嘉宾；此外，他还获得吉利德的研究资助，且是Illuminatio医疗技术公司的联合创始人。

详细信息

通信作者:
黄炜燊， wongv@cuhk.edu.hk （ORCID： 0000-0003-2215-9410）

计量
- 文章访问数: 241
- HTML全文浏览量: 58
- PDF下载量: 92
- 被引次数: 0
出版历程
- 收稿日期: 2025-05-26
- 录用日期: 2025-07-15
- 出版日期: 2025-09-25

The prevalence of metabolic dysfunction-associated fatty liver disease in Asia

Weishen HUANG^{1, 2
, ,
,}

1.
Medical Data Analysis Center，Department of Internal Medicine and Pharmacotherapy，Faculty of Medicine，The Chinese University of Hong Kong，Hong Kong 999077，China
2.
State Key Laboratory of Digestive Diseases，Institute of Digestive Diseases，The Chinese University of Hong Kong，Hong Kong 999077，China

Research funding:

General Research Fund of Hong Kong Research Grants Committee of China (14106923);

Direct Research Fund of the Chinese University of Hong Kong (2024.065);

China National Key R D Program (2023ZD0508700)

More Information

Corresponding author: HUANG Weishen， wongv@cuhk.edu.hk （ORCID： 0000-0003-2215-9410）

摘要

摘要: 代谢相关脂肪性肝病（MAFLD）作为全球常见慢性肝病，其全球患病率达30.1%，且呈持续上升趋势，其中拉丁美洲（44.4%）和亚洲地区的增长尤为显著，2010—2021年东亚地区增幅达16.6%。亚洲各地区之间MAFLD患病率亦存在明显地域差异：中国体检数据显示，肝脂肪变总体检出率为44.4%，其中华北地区（53.5%）显著高于华南地区（34.2%）；而日本与伊朗的患病率分别为22.3%和38.1%。该疾病与代谢异常存在密切关联，全球范围内65%的糖尿病患者合并MAFLD（亚太地区为53.2%），超重亚洲人群（BMI≥23 kg/m²）MAFLD的患病率达47.7%～63.4%，但非肥胖人群中仍有19.2%患病率（印度高达47.7%）。新诊断标准基于肝脂肪变+代谢异常组合，对慢性乙型肝炎高发的亚洲地区具有特殊意义，二者共存可能加速肝癌进展。亚洲地区正面临非肥胖型MAFLD比例高、至2030年MAFLD相关肝硬化并发症及肝癌死亡率将翻倍等独特挑战，虽然当前指南已推荐FIB-4分步筛查策略，但仍需提升基层医疗执行力和公众健康认知，亟需制订符合亚洲人群特征的早期干预方案，以应对这一重大公共卫生危机。
- 代谢相关脂肪性肝病 /
- 亚洲 /
- 流行病学
Abstract: Metabolic dysfunction-associated fatty liver disease （MAFLD） is a common chronic liver disease worldwide， with a global prevalence rate of 30.1%， and there is a tendency of increase in the prevalence rate of MAFLD， with a significant increase in Latin America （44.4%） and Asia， where the prevalence rate of MAFLD was increased by 16.6% from 2010 to 2021. There are notable regional differences within Asia. The Chinese physical examination data show that the overall detection rate of hepatic steatosis is 44.4%， and the detection rate in North China （53.5%） is significantly higher than that in South China （34.2%）； the prevalence rate is 22.3% in Japan and 38.1% in Iran. This disease is closely associated with metabolic disorder. Globally， 65% of diabetic patients have MAFLD （53.2% in the Asia-Pacific region）， and the prevalence rate of MAFLD in overweight Asian populations （BMI ≥23 kg/m²） reaches 47.7% to 63.4%， even with a prevalence rate of 19.2% （up to 47.7% in India） in non-obese individuals. The new diagnostic criteria are developed based on the combination of hepatic steatosis and metabolic disorder and are of particular significance in Asia with a high prevalence rate of chronic hepatitis B， and the coexistence of the two may accelerate the progression of liver cancer. Asia is facing unique challenges such as a high proportion of patients with non-obese MAFLD and doubling of the incidence rates of liver cirrhosis complications and the mortality rates of liver cancer in 2030. Although current guidelines recommend a stepwise screening strategy using FIB-4， there is still a need to enhance the implementation of primary care and the health awareness among the public and develop early intervention regimens tailored to the features of the Asian population， in order to address this major public health crisis.
- Metabolic Dysfunction-associated Fatty Liver Disease /
- Asia /
- Epidemiology

HTML全文

图 1 MAFLD在亚洲地区的患病率

Figure 1. Prevalence of metabolism-related fatty liver disease in Asia

下载: 全尺寸图片幻灯片

参考文献(33)

[1]	WONG VW, EKSTEDT M, WONG GL, et al. Changing epidemiology, global trends and implications for outcomes of NAFLD[J]. J Hepatol, 2023, 79( 3): 842- 852. DOI: 10.1016/j.jhep.2023.04.036.
[2]	YOUNOSSI ZM, GOLABI P, PAIK JM, et al. The global epidemiology of nonalcoholic fatty liver disease(NAFLD) and nonalcoholic steatohepatitis(NASH): A systematic review[J]. Hepatology, 2023, 77( 4): 1335- 1347. DOI: 10.1097/HEP.0000000000000004.
[3]	FENG G, TARGHER G, BYRNE CD, et al. Global burden of metabolic dysfunction-10. 1016/j.jhepr. 2024. 101271.
[4]	LI J, ZOU BY, YEO YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2019, 4( 5): 389- 398. DOI: 10.1016/S2468-1253(19)30039-1.
[5]	MAN S, DENG YH, MA Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: A nationwide study with 5.7 million adults in China[J]. Gastroenterology, 2023, 165( 4): 1025- 1040. DOI: 10.1053/j.gastro.2023.05.053.
[6]	WONG VW, HUI AY, TSANG SW, et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2006, 4( 9): 1154- 1161. DOI: 10.1016/j.cgh.2006.06.011.
[7]	ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73( 1): 202- 209. DOI: 10.1016/j.jhep.2020.03.039.
[8]	FAN JG, XU XY, YANG RX, et al. Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease(version 2024)[J]. J Clin Transl Hepatol, 2024, 12( 11): 955- 974. DOI: 10.14218/JCTH.2024.00311.
[9]	WONG VW, WONG GL, WOO J, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease[J]. Clin Gastroenterol Hepatol, 2021, 19( 10): 2161- 2171. e 5. DOI: 10.1016/j.cgh.2020.10.046.
[10]	SONG SJ, LAI JC, WONG GL, et al. Can we use old NAFLD data under the new MASLD definition?[J]. J Hepatol, 2024, 80( 2): e54- e56. DOI: 10.1016/j.jhep.2023.07.021.
[11]	En Li CHO E, ANG CZ, QUEK J, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis[J]. Gut. 2023, 72( 11): 2138- 2148. DOI: 10.1136/gutjnl-2023-330110.
[12]	YOUNOSSI ZM, GOLABI P, PRICE JK, et al. The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes[J]. Clin Gastroenterol Hepatol, 2024, 22( 10): 1999- 2010.e8. DOI: 10.1016/j.cgh.2024.03.006.
[13]	ZHANG XR, WONG GL, YIP TC, et al. Risk of liver-related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease[J]. Hepatology, 2022, 76( 5): 1409- 1422. DOI: 10.1002/hep.32476.
[14]	ZHANG XR, YIP TC, TSE YK, et al. Duration of type 2 diabetes and liver-related events in nonalcoholic fatty liver disease: A landmark analysis[J]. Hepatology, 2023, 78( 6): 1816- 1827. DOI: 10.1097/HEP.0000000000000432.
[15]	KWOK R, CHOI KC, WONG GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: A prospective cohort study[J]. Gut, 2016, 65( 8): 1359- 1368. DOI: 10.1136/gutjnl-2015-309265.
[16]	LEE HW, WONG GL, KWOK R, et al. Serial transient elastography examinations to monitor patients with type 2 diabetes: A prospective cohort study[J]. Hepatology, 2020, 72( 4): 1230- 1241. DOI: 10.1002/hep.31142.
[17]	ZHANG XR, YIP TC, WONG GL, et al. Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: A randomised controlled trial[J]. Gut, 2023, 72( 12): 2364- 2371. DOI: 10.1136/gutjnl-2023-330269.
[18]	FAN JG, KIM SU, WONG VW. New trends on obesity and NAFLD in Asia[J]. J Hepatol, 2017, 67( 4): 862- 873. DOI: 10.1016/j.jhep.2017.06.003.
[19]	QUEK J, CHAN KE, WONG ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2023, 8( 1): 20- 30. DOI: 10.1016/S2468-1253(22)00317-X.
[20]	YE Q, ZOU BY, YEO YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2020, 5( 8): 739- 752. DOI: 10.1016/S2468-1253(20)30077-7.
[21]	WONG VW, WONG GL, YEUNG DK, et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: A population study with paired proton-magnetic resonance spectroscopy[J]. J Hepatol, 2015, 62( 1): 182- 189. DOI: 10.1016/j.jhep.2014.08.041.
[22]	WONG VW, WONG GL, CHU WC, et al. Hepatitis B virus infection and fatty liver in the general population[J]. J Hepatol, 2012, 56( 3): 533- 540. DOI: 10.1016/j.jhep.2011.09.013.
[23]	MAO XH, CHEUNG KS, PENG CZ, et al. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis[J]. Hepatology, 2023, 77( 5): 1735- 1745. DOI: 10.1002/hep.32792.
[24]	SHIN HS, JUN BG, YI SW. Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases[J]. Clin Mol Hepatol, 2022, 28( 4): 773- 789. DOI: 10.3350/cmh.2021.0383.
[25]	FAN R, NIU JQ, MA H, et al. Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy[J]. Aliment Pharmacol Ther, 2021, 54( 3): 329- 338. DOI: 10.1111/apt.16469.
[26]	ESTES C, ANSTEE QM, ARIAS-LOSTE MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J]. J Hepatol, 2018, 69( 4): 896- 904. DOI: 10.1016/j.jhep.2018.05.036.
[27]	ESTES C, CHAN HLY, CHIEN RN, et al. Modelling NAFLD disease burden in four Asian regions-2019-2030[J]. Aliment Pharmacol Ther, 2020, 51( 8): 801- 811. DOI: 10.1111/apt.15673.
[28]	TATEISHI R, UCHINO K, FUJIWARA N, et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update[J]. J Gastroenterol, 2019, 54( 4): 367- 376. DOI: 10.1007/s00535-018-1532-5.
[29]	KANWAL F, SHUBROOK JH, ADAMS LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2021, 161( 5): 1657- 1669. DOI: 10.1053/j.gastro.2021.07.049.
[30]	RINELLA ME, NEUSCHWANDER-TETRI BA, SIDDIQUI MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77( 5): 1797- 1835. DOI: 10.1097/HEP.0000000000000323.
[31]	European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease(MASLD)[J]. J Hepatol, 2024, 81( 3): 492- 542. DOI: 10.1016/j.jhep.2024.04.031.
[32]	CUSI K, ABDELMALEK MF, APOVIAN CM, et al. Metabolic dysfunction-associated steatotic liver disease(MASLD) in people with diabetes: The need for screening and early intervention. A consensus report of the American diabetes association[J]. Diabetes Care, 2025, 48( 7): 1057- 1082. DOI: 10.2337/dci24-0094.
[33]	YIP TC, LEE HW, LIN HP, et al. Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease[J]. J Hepatol, 2025, 83( 2): 304- 314. DOI: 10.1016/j.jhep.2025.01.014.